Articles tagged with Multiple Myeloma
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A multi-institutional trial found that ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients, with 81% achieving pain control without additional radiation. Treatment side effects were limited to low-grade fatigue.
A Phase 1 clinical trial found that an investigational CAR-T therapy, anito-cel, led to high response rates and durable benefits in patients with relapsed/refractory multiple myeloma. Serious side effects were uncommon, and no delayed neurological complications were reported.
Advances in blood cancer treatment have saved 25.8 million life-years, with significant gains for Hodgkin lymphoma and non-Hodgkin lymphoma patients. However, Black patients and those with acute myeloid leukemia (AML) continue to experience worse outcomes, highlighting the need for continued research investment.
Researchers developed a first-in-class therapy targeting MYC, a protein involved in 70% of cancers, by disrupting its relationship with GSPT1. This approach showed strong anti-cancer activity in multiple types of blood cancers, including treatment-resistant models.
Research reveals that patients' inherited genetic variants can impact the benefits and toxicity of CAR-T cell therapy for blood cancers. Variants in genes such as STXBP2, ADAMTSL3, and PTPN22 were found to correlate with treatment-related toxicity or enhanced therapeutic activity.
Cevostamab, a bispecific antibody targeting FcRH5, showed promise in treating multiple myeloma, with over 40% of patients experiencing cancer reduction. The fixed-duration approach provided a break from treatment for patients, reducing serious infections and adverse events.
Researchers found that a new treatment regimen can slow cancer progression in patients with functional high-risk (FHR) multiple myeloma. The study defines FHR multiple myeloma as progressing within 36 months of starting treatment, indicating a survival prognosis of less than 2 years after progression.
The ECOG-ACRIN ENDURANCE trial found that indefinite lenalidomide maintenance had no survival benefit and more toxicity compared to stopping treatment after 2 years in patients not undergoing a stem cell transplant. The study suggests that fixed duration treatment can significantly reduce healthcare costs.
A Mayo Clinic-led study found that continuing maintenance therapy beyond two years did not improve overall survival for patients with standard-risk multiple myeloma. The findings suggest that treatment duration can be safely tailored, reducing treatment burden and costs.
Researchers created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The study identified five distinct subtypes, or 'ecotypes,' that capture meaningful insights into signaling pathways and genetic programs not fully explained by disease stage alone.
Researchers have developed an innovative combination treatment strategy that uses cells' waste removal functions to effectively dismantle multiple myeloma. The experimental targeted protein degrader enhances the destruction of a specific cancer cell survival protein and works in tandem with existing drugs, while showing limited toxicity.
A new study suggests that wearable monitoring can detect cytokine release syndrome (CRS) hours before standard hospital monitoring, potentially reducing complications and improving patient outcomes. The findings support the use of wearable technology to expand access to CAR-T therapy and reduce reliance on prolonged hospital stays.
The Sylvester Cancer Institute has made significant breakthroughs in multiple myeloma treatment with the immunotherapy drug teclistamab, which extends remission and survival rates. Additionally, research has shed light on glioma evolution after treatment and identified genetic markers for aggressive solitary fibrous tumors.
A new immunotherapy combination has shown promise in delaying cancer progression and improving survival for patients with multiple myeloma. The study found that nearly nine in 10 patients receiving the treatment experienced a shrinkage of their cancer, compared to about eight in 10 on standard treatment.
The phase 2 ImmunoPRISM trial shows teclistamab significantly improves outcomes for patients with high-risk smoldering multiple myeloma. The BCMA-targeted bispecific antibody outperformed lenalidomide plus dexamethasone, pointing to the potential value of using immune-based therapy earlier in the course of the disease.
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
In a landmark international trial, teclistamab outperformed standard treatments in extending survival and remission for patients with relapsed multiple myeloma. Nearly 70% of patients remained disease-free after 18 months, and nearly two-thirds achieved complete remission.
Researchers developed an AI-based tool to predict patient outcomes and tailor treatment strategies for newly diagnosed multiple myeloma patients. The analysis revealed that low CD16 levels were associated with shorter time to next treatment, improving disease control and quality of life.
Researchers from The University of Osaka discovered that only a small proportion of CD8 T cells undergo sustained clonal expansion in multiple myeloma immunotherapy, leading to the strongest anti-tumor response. Early immune activity could help predict which cells will become effective cancer fighters.
Researchers discovered that mezigdomide can reinvigorate exhausted T cells and enhance immunotherapies. The drug works by degrading key gene regulators Ikaros and Aiolos, which sustain genetic and epigenetic programs keeping T cells in an exhausted state.
Researchers at Winship Cancer Institute have administered the first investigational in vivo CAR-T cell therapy in the US for relapsed and refractory multiple myeloma, marking a significant milestone in next-generation cellular therapies. The therapy aims to streamline treatment processes and eliminate delays in care.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
A new study found a clear shift in mortality trends in multiple myeloma closely parallels major therapeutic advances. Targeted therapies, including immunomodulatory drugs and CAR T-cell therapies, have significantly improved disease control and induced deep responses.
A phase II clinical trial found that ciltacabtagene autoleucel, a CAR T-cell therapy, achieved a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma. The treatment also showed low-grade cytokine release syndrome and transient hematologic toxicities.
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
A University of Calgary-led study found that multiple myeloma tumour cells adapt in multiple ways to become resistant to treatment, highlighting the need for personalized cancer therapy. The research aims to develop next-generation treatments designed to anticipate and overcome these changes.
Researchers used machine learning methods to identify safe time windows for outpatient stem cell therapy in multiple myeloma patients. The study found that this approach can predict adverse events and enable more precise risk assessment.
A new predictive tool, PANGEA-SMM, more accurately determines when smoldering multiple myeloma is progressing and requires treatment. The free online tool uses dynamic biomarkers to track patient progression and identifies patients at high risk of developing active cancer.
Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.
A new study published in CANCER found that men are more likely to have advanced disease and high myeloma load at diagnosis compared to women. Men were also less likely to have low bone mineral density and had different chromosomal abnormalities, which may contribute to the sex disparity in multiple myeloma risk.
Researchers created an 'atlas' of immune cells in bone marrow cancer that provides insights into how the immune system interacts with cancerous plasma cells. The knowledge can improve survival predictions and guide treatment decisions for patients with multiple myeloma.
Researchers analyzed nearly 1.5 million immune cells from bone marrow samples of 335 newly diagnosed multiple myeloma patients, revealing previously hidden patterns in immune system behavior. The study provides unprecedented insight into immune dysfunction in myeloma and could lead to improved tools for predicting patient relapse risk.
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
CORAL accurately predicts genetic subtypes and patient outcomes in multiple myeloma without costly genomic tests. The technology could be applied to other cancers, opening the door to personalized, faster and widely accessible cancer care.
A new trial found that the Tec-Dara combination of teclistamab and daratumumab significantly improved progression-free survival in patients with R/R multiple myeloma, achieving an 83.4% rate compared to 29.7% for standard therapies. The treatment also showed better quality of life outcomes and was comparable in safety profile.
A Fox Chase Cancer Center study found that outpatient observation significantly reduced hospital stays with no adverse safety events reported. The structured model also freed up inpatient beds and cut healthcare costs.
Researchers found that CAR T cell therapy side effects, such as neurotoxicity and intestinal inflammation, are linked to high rates of death unrelated to cancer relapse. CirAEs were more common in patients who received cilta-cel and had higher non-relapse mortality rates.
The Phase II trial of anito-cel demonstrated a high overall response rate of 97% and complete response rate of 68% in patients with refractory multiple myeloma. The therapy also showed a favorable safety profile, with manageable side effects.
A clinical trial found that linvoseltamab, a bispecific antibody, eliminated 90% of tumor cells in patients with residual disease. The treatment allows patients to bypass high-dose chemotherapy and bone marrow transplants, potentially improving long-term outcomes.
A Mount Sinai study found that diverse T cells and low immunosuppressive myeloid cells are key to long-term remission after CAR T cell therapy. Patients with these immune features remained cancer-free for more than five years, while others relapsed sooner.
City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.
Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.
A new study reveals that combining proteasome inhibitors with Lys05 can effectively kill AML cells by disabling backup survival pathways. This approach has shown promise in preclinical models and could lead to improved treatment options for a wider range of AML patients.
Recent studies from Sylvester have uncovered links between breast cancer, Superfund sites and social adversity. Researchers are also exploring the use of artificial intelligence (AI) in interpreting mammograms more accurately.
Researchers identify three primary UPR pathways and their downstream cascades, which play a crucial role in the differentiation of osteoblasts and osteoclasts. Targeting these pathways with emerging drugs may alleviate bone-related events and kill tumors localized in bones.
Researchers identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment for multiple myeloma and other cancers. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma.
Duke University researchers discovered that inhibiting an enzyme involved in iron regulation makes cancer cells vulnerable to cell death. By targeting STK17B kinase, they reactivated ferroptosis and increased the effectiveness of conventional therapies against multiple myeloma.
Researchers reprogrammed the epigenetic code to affect tumour growth and survival in multiple myeloma. This study presents a comprehensive map of epigenetic alterations in multiple myeloma, highlighting site-specific increases in DNA and protein methylation that control gene activity.
Researchers at The Mount Sinai Hospital successfully treated a rare and aggressive T-cell lymphoma that developed after CAR T-cell therapy for multiple myeloma. They identified a combination of compounds approved by the FDA that effectively targeted the lymphoma, with one compound, anti-CCR4, showing particular promise.
A new study reveals that DNA damage in multiple myeloma initiates 2-4 decades before diagnosis, with key genomic events including IGH translocation and chr 1q gain. These findings may lead to new precision medicine treatment strategies for patients.
Researchers at Dana-Farber Cancer Institute have developed a non-invasive blood test, SWIFT-seq, to profile circulating tumor cells in the blood. The test offers a detailed genetic profile, identifying key genetic changes crucial for understanding multiple myeloma.
MiROM identifies proteins by detecting molecular vibrations and detects structural changes in proteins, such as misfolding, allowing for real-time assessments of treatment effectiveness. This technology holds great potential for other diseases linked to protein misfolding, including Alzheimer's and Parkinson's.
A retrospective study found teclistamab-cqyv to be effective in patients with high-risk, heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. The bispecific antibody reduced disease burden by at least half in 53% of evaluable patients, and 45% achieved a 'very good partial response'. Despite a hi...
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
A high-fiber plant-based diet improved health markers that could delay the progression of precancerous conditions and multiple myeloma. The study showed significant improvements in dietary quality, weight loss, metabolic markers, inflammation, and gut microbiome diversity.
A new four-drug combination, DKRd, has emerged as a highly effective and safe treatment for newly diagnosed multiple myeloma patients. The ADVANCE clinical trial shows that 59% of patients treated with DKRd were MRD-negative after eight cycles of treatment, compared to 36% of KRd-treated patients.
Researchers at MD Anderson Cancer Center have made significant discoveries in three key areas of cancer care. In a study on sickle cell disease, the team found that the disorder can suppress immunity by altering DNA structure in CD8+ T cells, leading to potential strategies for improving immunotherapy responses. Meanwhile, a biomarker-...
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.